2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor

Related Products

PDF 2.76 MB

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19998
    Taprenepag isopropyl
    		Agonist 99.23%
    Taprenepag isopropyl is a highly selective EP2 receptor agonist.
    Taprenepag isopropyl
  • HY-153129
    EP2 receptor antagonist-2
    		Antagonist 98.69%
    EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA).
    EP2 receptor antagonist-2
  • HY-105005
    Crisdesalazine
    		Control 98.92%
    Crisdesalazine (AAD-2004) is an anti-inflammatory agent that simultaneously blocks inflammation mediated by free radicals and prostaglandin E2 (PGE2). Crisdesalazine (AAD-2004) can be used to study neurodegeneration in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
    Crisdesalazine
  • HY-B0428B
    Ozagrel hydrochloride
    		Inhibitor 99.86%
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
    Ozagrel hydrochloride
  • HY-101813
    Laflunimus
    		Inhibitor 99.70%
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
    Laflunimus
  • HY-B0428A
    Ozagrel sodium
    		Inhibitor 99.82%
    Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
    Ozagrel sodium
  • HY-145684
    EP2 receptor antagonist-1
    		Antagonist 99.84%
    EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effects.
    EP2 receptor antagonist-1
  • HY-16635
    Setipiprant
    		Antagonist 98.23%
    Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC50 value of 6 nM. Setipiprant inhibits prostanoid receptors hDP1 and hEP2 with IC50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis.
    Setipiprant
  • HY-118609
    EP4 receptor agonist 2
    		Agonist 99.0%
    EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC50 value of 0.8 nM; Ki values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively.
    EP4 receptor agonist 2
  • HY-15342A
    Timapiprant sodium
    		Inhibitor 99.61%
    Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils.
    Timapiprant sodium
  • HY-12956A
    Dinoprost tromethamine salt
    		Agonist 98.0%
    Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour.
    Dinoprost tromethamine salt
  • HY-N2252
    Licarin A
    		Inhibitor 99.83%
    Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression.
    Licarin A
  • HY-N1401
    20(R)-Ginsenoside Rh2
    		Inhibitor 99.84%
    20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect.
    20(R)-Ginsenoside Rh2
  • HY-142658A
    BAY-6672 hydrochloride
    		Antagonist 98.01%
    BAY-6672 hydrochloride is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
    BAY-6672 hydrochloride
  • HY-B1074
    Ethamsylate
    		Inhibitor 99.49%
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
    Ethamsylate
  • HY-113459
    Prostaglandin F1a
    		98.10%
    Prostaglandin F1a is a compound that has the effect of contracting smooth muscle and lowering blood pressure.
    Prostaglandin F1a
  • HY-19360
    Sulprostone
    		Agonist ≥99.0%
    Sulprostone (SHB 286) is a potent and selective EP3 receptor agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects. Sulprostone has potential for the research of pregnancy termination and hemorrhages during delivery.
    Sulprostone
  • HY-12184
    ONO-AE 248
    		Agonist 98.27%
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels.
    ONO-AE 248
  • HY-U00027
    Quinotolast sodium
    		Inhibitor 98.38%
    Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner.
    Quinotolast sodium
  • HY-108415
    Cloprostenol sodium salt
    		Agonist 99.52%
    Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF2α receptor agonist.
    Cloprostenol sodium salt
Cat. No. Product Name / Synonyms Application Reactivity
Prostaglandin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.